Management of Acute Myeloid Leukemia: A Review.
Publication/Presentation Date
2-18-2026
Abstract
BACKGROUND/OBJECTIVES: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with historically poor outcomes, particularly among older adults and patients harboring high-risk molecular features. Advances in genomic profiling have enabled the development of targeted therapies, reshaping treatment algorithms beyond conventional cytarabine-anthracycline induction and hypomethylating agent-based regimens. This review summarizes current evidence and emerging therapeutic strategies across four evolving areas: menin inhibition,
METHODS: We reviewed published clinical trials, preclinical studies, and ongoing clinical trials evaluating targeted therapies in AML. Emphasis was placed on agents with regulatory approval or substantial clinical development, including menin inhibitors,
RESULTS: Menin inhibitors have demonstrated significant activity in
CONCLUSIONS: Targeted therapies have improved outcomes in molecularly defined subsets of AML, with menin,
Volume
18
Issue
4
ISSN
2072-6694
Published In/Presented At
Jeurkar, C., King, L., Baek, D., Wilde, L., Keiffer, G., & Kasner, M. (2026). Management of Acute Myeloid Leukemia: A Review. Cancers, 18(4), 659. https://doi.org/10.3390/cancers18040659
Disciplines
Medicine and Health Sciences
PubMedID
41749912
Department(s)
Hematology-Medical Oncology Division
Document Type
Article